Palatin Technologies (PTN) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2015 Results
September 21, 2015 7:30 AM EDTCRANBURY, N.J., Sept. 21, 2015 /PRNewswire/ --Â Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2015.Â
Fiscal Year Ended June 30, 2015 and Recent Highlights
Bremelanotide development for Female Sexual Dysfunction (FSD): Palatin initiated Protocols 301 and 302 of its Phase 3 reconnect study in the United States and Canada for the treatment of FSD in December 2014 and... MorePalatin Technologies and Richter Terminate License Agreement for Bremelanotide for Female Sexual Dysfunction
September 21, 2015 7:00 AM EDTCRANBURY, N.J., Sept. 21, 2015 /PRNewswire/ --Â Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that the Company and Gedeon Richter (Richter) mutually and amicably agreed to terminate the license and collaboration agreement for bremelanotide for the treatment of female sexual dysfunction (FSD). All rights and licenses granted to Richter have terminated and reverted back to Palatin. There are no payment or reimbursement obligations as a result of the license agreement... More
